Hypertriglyceridaemia (HTG) is an important risk factor for metabolic fatty liver disease – an umbrella term for multiple common chronic liver diseases for which triglyceride-lowering agents are starting to show encouraging benefits. Professor Robert Rosenson (Icahn School of Medicine at Mount Sinai, New York, USA) examines the evidence linking triglycerides to fatty liver disease and current and potential approaches to treatment.
